Targeting specific proteins and signaling pathways in pediatric leukemia.
Co-targeting BET Bromodomain Proteins and Aberrant Signaling in AML.
This study is looking at new combinations of drugs to help kids and young adults with acute myeloid leukemia (AML) get better treatment, by figuring out how these drugs can work together and why some might not work as well, so we can find better ways to fight this tough illness.
Quick facts
| Grant type | Career grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California, San Francisco NIH-funded |
| Lab location | 1 site (San Francisco, United States) |
| Project ID | NIH-10887557 on NIH RePORTER |
What this research studies
This research focuses on improving treatment outcomes for children and young adults with acute myeloid leukemia (AML) by investigating new drug combinations that target both abnormal transcriptional programs and signaling pathways. The approach involves studying how these drugs work together to enhance their effectiveness and understanding the mechanisms that may lead to resistance. By using patient-derived xenograft models, the research aims to evaluate the efficacy of these combinations in a real-world context, providing insights that could lead to better therapies for this challenging disease.
Who could benefit from this research
Good fit: Ideal candidates for this research are children and young adults diagnosed with acute myeloid leukemia.
Not a fit: Patients with other types of leukemia or those who are not within the pediatric or young adult age range may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for pediatric AML, potentially improving survival rates and reducing treatment-related toxicities.
How similar studies have performed: Previous research has shown promise in targeting similar pathways in adult AML, suggesting that this approach may also be effective in pediatric populations.
Where this research is happening
San Francisco, United States
- University of California, San Francisco — San Francisco, United States (Active)
Researchers
- Principal investigator: Huang, Benjamin — University of California, San Francisco
- Study coordinator: Huang, Benjamin
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.